P roductive humoral immune responses against thymusdependent Ags require cognate interactions between B cells
and Th cells (1, 2) . Along with specific TCR-peptide-MHC class II interactions, the engagement of CD40 on B cells and CD154 expressed by activated CD4 T cells is critical for cognate T cell help (3) . Genetic defects in CD40 or its ligand or therapeutic interference with CD40-CD154 pathway result in impairment in germinal center formation, isotype switching, and high-affinity Ab production in response to thymus-dependent Ags in mice and humans (4) (5) (6) (7) (8) (9) .
Analogous to immune responses against infections and model Ags, the generation of high-affinity donor-reactive alloantibodies after transplantation is dependent on T cell help and CD40-CD154 costimulation (7, 10, 11) . Blocking the CD40-CD154 pathway inhibited donor-specific T cell responses, prevented generation of antidonor alloantibodies, and facilitated prolonged graft survival and often tolerance in multiple rodent transplant models (12) (13) (14) (15) (16) . However, the same therapies were much less efficacious when applied to nonhuman primates (17) (18) (19) . Compared with inbred rodents housed in pathogen-free facilities, large animals and humans contain many more alloreactive memory T cells arising from previous exposure to alloantigens and infectious agents with cross-reactivity to alloantigens (defined as heterologous immunity) or from homeostatic expansion after lymphopenia (20, 21) . During the past decade, several groups including ours established that donor-reactive memory T cells present in transplant recipients can confer resistance to the effects of conventional costimulatory blockade (22) (23) (24) (25) (26) .
B cell activation and class switch recombination are regulated by cytokines secreted by differentiated CD4 T cell subsets. Although the roles of IL-4 and IFN-g in Ab responses are well established (27) (28) (29) , IL-17 has also been reported to promote germinal center development and humoral responses in autoimmune-prone mice (30) . Using a mouse model of heart transplantation, we recently reported that donor-reactive memory CD4 T cells can deliver help to B cells and induce high titers of IgG alloantibodies in the absence of CD40-CD154 interactions, and that the induced alloantibodies contribute to heart allograft injury (31) . Notably, donor-specific memory CD4 T cells induced via in vitro or in vivo priming in our studies were heterogeneous in their phenotype and cytokine profile. Thus, the identity of memory helper cells capable of inducing alloantibodies in a CD40-independent manner, as well as the molecular requirements for such help, remained unclear. These issues have direct relevance to clinical transplantation as several reagents targeting CD40-CD154 costimulatory pathway are being developed and tested in preclinical transplantation models (32) (33) (34) .
The T cell repertoire of many humans contains memory CD4 T cells polarized to the Th1, Th2, and Th17 functional phenotypes that are likely to be alloreactive (35, 36) . The abilities of differentiated CD4 Th cell subsets to initiate alloantibody production, and thus inflict allograft pathology in the presence or absence of CD40-CD154 costimulation, have not been previously investigated. In this study, we demonstrate that similar to unpolarized memory CD4 T cells, memory Th1 and Th17 cells induce high titers of anti-donor IgG in response to heart allografts placed in CD40 2/2 recipients. Alloantibodies induced by Th17 cells, however, had marked decreases in reactivity to donor MHC class I molecules and inferior potency to induce C4d deposition in the heart allograft vasculature compared with alloantibodies induced by Th1 cells. Unexpectedly, Th2 cells with the same specificity failed to provide CD40-independent help for IgG alloantibody generation. Furthermore, recipient treatment with anti-IFN-g mAb inhibited IgG alloantibody responses initiated by memory CD4 T cells in both CD40 2/2 and wild type recipients treated with anti-CD154 mAb. These studies indicate that the ability of memory CD4 Th T cells to produce IFN-g determines both the isotype and the specificity of donor-reactive alloantibodies and can thus affect allograft pathology. The results should be valuable in identifying transplant patients at risk for de novo development of pathogenic alloantibodies and for preventing alloantibody production in T cell-sensitized recipients. 
Materials and Methods

Animals
Generation of alloreactive memory CD4 T cells
Memory Mar CD4 T cells were generated as previously published (23) . In brief, spleen cells from young (4-6 wk) Mar female mice were stimulated in vitro with 3 mM HY Dby peptide (NAGFNSNRANSSRSS; Research Genetics, Huntsville, AL). After 4 d, cells were washed, counted, and i.v. injected into naive B6 or CD40 2/2 female mice (5 3 10 6 cells/mouse or fewer in selected experiments). In each experiment, recipients received cells derived from a common pool of activated Mar T cells. Animals were rested for 3 wk before use as heart allograft recipients. To generate polarized subsets of Mar cells, we cultured naive CD45.1 Mar spleen cells for 4 d with 3 mM HY Dby p and one of the following: 1) 10 ng/ml rIL-12 (Peprotech, Rocky Hill, NJ) and 10 mg/ml anti-IL-4 mAb (BD Pharmingen, San Diego, CA) for Th1 polarization; 2) 200 ng/ml rIL-4 (Peprotech), 10 mg/ml anti-IL-12 and 10 mg/ml anti-IFN-g mAb (both from BD Pharmingen) for Th2 polarization; and 3) 5 ng/ml rTGF-b (R&D Systems, Minneapolis, MN), 10 ng/ml rIL-6 (Peprotech), 10 mg/ml anti-IFN-g, and 10 mg/ml anti-IL-4 mAb for Th17 polarization. An aliquot of polarized harvested cells was washed, counted, and tested for their ability to secrete IFN-g, IL-4, IL-2, and IL-17 in response to HYDby peptide in a recall ELISPOT assay as previously published (23, (38) (39) (40) . The remaining polarized CD4 T cells were injected i.v. into groups of CD40 2/2 female mice (5 3 10 6 cells/mouse) followed by 3 wk of rest and the placement of an allogeneic BALB/c cardiac allograft. 
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lo by flow cytometry (data not shown).
Heart transplantation and recipient treatment
Vascularized heterotopic cardiac allografts were placed and monitored as previously described (23, 40) . Rejection was defined as a loss of palpable heartbeat and confirmed by laparotomy. When indicated, wild type B6 recipients were treated with anti-CD154 Ab (clone MR1) 1 d before the surgery (1 mg via i.v. injection; Bio X Cell, West Lebanon, NH). Antimouse IFN-g mAb (rat IgG2b, clone 7E.17G9; Bio X Cell) or control rat IgG (Sigma-Aldrich, St. Louis, MO) was injected i.p. on days 0, 2, 4, 6, and every 5 d thereafter (0.5 mg/mouse/injection).
Histologic examination of recipient spleen tissues
For immunohistochemistry, tissues were fixed with acid methanol (60% methanol, 10% acetic acid). Paraffin-embedded sections (5 mm) were steamed in two changes of Trilogy-EDTA, pH 8 (Cell Marque, Hot Springs, AR) for 1 h. Endogenous peroxidase activity was blocked by incubation with 0.3% H 2 O 2 in 80% methanol, and nonspecific protein interactions were blocked by incubation with a serum-free protein block (DAKO, Carpinteria, CA). Slides were incubated with a 1:3000 dilution of biotin-SPconjugated affinity-purified F(ab9) 2 fragments of goat Abs specific for Fcg of mouse IgG (Jackson Immunoresearch, West Grove, PA) for 60 min at room temperature. Slides were subsequently incubated for 30 min with avidinbiotin-enzyme complex (ABC elite PK6100; Vector, Burlingame, CA), followed by diaminobenzidine and counterstained with hematoxylin.
Flow cytometry
Fluorochrome-labeled Abs for T cell phenotype analysis were purchased from BD Pharmingen (San Diego, CA) or from eBioscience (San Diego, CA). Cells were isolated from peripheral blood or spleen, bone marrow, lung, and liver and stained with indicated reagents as previously described (23, 40, 41 
Cytokine ELISPOT assay
Assays were performed as previously described using capture and detecting anti-mouse IFN-g, anti-mouse IL-2, anti-mouse IL-4, and anti-mouse IL-17 mAb from BD Pharmingen (39, 42) . Recipient spleen cells were stimulated with mitomycin C-treated donor BALB/c, third-party SJL, or self B6 spleen cells or with HY Dby peptide for 24 h. Responder cells were titrated from 400,000 to 20,000 per well with the addition of 400,000 stimulator cells/well. The resulting spots were analyzed using an ImmunoSpot Series 4 analyzer (Cellular Technology, Cleveland, OH).
Measurement of serum alloantibody titers
Donor BALB/c, third-party SJL, and congenic B6.K d thymocytes were isolated, and 1 3 10 6 cell aliquots were incubated with 100 ml of serially diluted recipient serum. PE-conjugated anti-mouse IgG1, FITC-conjugated anti-mouse IgG2a, FITC-conjugated anti-mouse IgG3, and biotinylated anti-mouse IgG2b followed by PE-streptavidin conjugate were used as detecting Abs at a 1:50-100 dilution (all from BD Pharmingen). Rat anti-mouse IgG2a mAb R19-15 used in our studies was raised against pooled BALB/c and C57BL/6 Ig, and thus has reactivity to both IgG2a and IgG2c. The staining was performed as previously published by our group (43, 44) . Cells were washed, fixed in 1% paraformaldehyde, and analyzed by flow cytometry. For every sample and every IgG isotype, the mean fluorescence intensity of each dilution was determined. The dilution that returned the MCF to the level observed when thymocytes were stained with an 1:90 dilution of naive B6 serum was divided by 2 and reported as the titer. Binding to B6.K d target cells was presented as mean fluorescence intensity at different serum dilutions.
IgG ELISPOT assay
The frequencies of IgG-and IgM-secreting Ab-secreting cells (ASCs) were determined using ELISPOT PLUS for mouse IgG and IgM kits (MABTECH AB, Nacka Strand, Sweden) as previously published (31, 43) . In brief, recipient cells isolated from spleen were cultured for 20 h in RPMI media supplemented with 5% of FBS in 96-well plates coated with anti-mouse IgG Ab. Then, either biotinylated anti-IgG, biotinylated anti-IgM, or biotinylated D d molecules (5 mg/ml, provided by the National Institutes of Health Tetramer Core Facility at Emory University, Atlanta, GA) was added as detection reagent for 2 h at room temperature. After extensive washes, the plates were incubated with streptavidin-alkaline phosphatase for 1 h at room temperature followed by BCIP/NBT substrate. The numbers of spots per well and the cumulative spot size distribution were analyzed using an ImmunoSpot Series 2 Analyzer (Cellular Technology, Shaker Heights, OH).
RNA isolation and quantitative real-time PCR analysis
Harvested spleens were immediately frozen by immersion into liquid nitrogen. Total RNA was isolated from individual samples using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Reverse transcription was performed using the High-Capacity cDNA Reverse Transcription Kit, quantitative real-time PCR was done on a 7500 Fast Real-Time PCR System instrument using TaqMan Fast Universal PCR Master Mix (2X), No AmpEraseUNG (all from Applied Biosystems, Foster City, CA). Probes and primers were from TaqMan gene expression assay reagents (Applied Biosystems): BAFF (Mm00446347_m1), APRIL (Mm03809849_s1), BAFFR (Mm00840578-g1), and TACI (Mm00840182_m1). Data were normalized to Mrpl 32 RNA amplification level in each sample and calculated relative to the expression of the target gene in total spleen cells isolated from CD40 2/2 recipients of BALB/c heart allografts or in CD45 2 spleen cells isolated from wild type B6 recipients of BALB/c heart allografts.
Statistical analysis
Statistical analyses to determine differences between groups for flow cytometry assays and recall immune responses were performed using a nonparametric equivalent of one-way ANOVA, the Kruskal-Wallis test. When the overall p value was ,0.05, pairwise comparisons were carried out using the nonparametric Mann-Whitney U test. A p value ,0.05 was considered statistically significant. Heart allograft survival was compared between groups by Kaplan-Meier analysis.
Results
Differentiation pathway of memory CD4 T cells determines their ability to provide CD40-independent help
We recently reported that donor-reactive memory CD4 T cells can provide help for the induction of donor-reactive IgG alloantibodies in the absence of CD40-CD154 interactions (31) . To extend these studies by comparing helper functions of naive and memory CD4
T cells with the same specificity, we used TCR transgenic mice (Mar) on B6.RAG2 In our previous studies, in vitro-primed memory Mar T cells were heterogeneous in their cytokine profile: 26 6 8% cells secreted IFN-g, 11 6 4% IL-4; 7 6 4% IL-2; and 2.5 6 1.4% IL-17. To begin to address the cytokine requirements for CD40-independent help by memory CD4 T cells, we tested the ability of differentiated memory CD4 helper subsets to induce alloantibodies in a CD40-independent fashion. Naive Mar cells were activated in vitro with HY Dby peptide and polarized toward Th1, Th2, and Th17 phenotypes by the addition of cytokines plus cytokine neutralizing Ab (Fig. 1A) . The extent of polarization was assessed by ELISPOT assay (Fig. 1B) , and the resulting cells were injected into CD40 2/2 B6 (H-2 b ) female mice. After 21 d of in vivo rest, the numbers of the transferred Th2 and Th17 cell subsets were comparable, whereas Th1 polarized cells demon- 2/2 female mice followed by a male BALB/c heart transplantation 3 wk later. The percentages of CD4 + CD45.1 + cells were evaluated by flow cytometry in the peripheral blood 3 wk after adoptive transfer (C) and in the spleen 2 wk after heart allograft placement (D). n = 5-7 mice/group. strated even better survival (Fig. 1C) . All mice then received BALB/c (H-2 d ) male heart allografts. Two weeks after transplantation, transferred Mar CD4 T cells were detectable in recipients' spleens at comparable frequencies (Fig. 1D) (Fig. 2) . Despite the absence of help for alloantibody production, Th2 memory T cells efficiently induced endogenous CD8 T cell alloresponses in the absence of CD40 (Fig. 2B) . We also performed parallel adoptive transfer of the memory T cell subsets into CD40-sufficient CD4 2/2 mice. In this setting, Th2-polarized Mar memory T cells induced high titers of anti-donor IgG1 and IgG2b Ab with intermediate titers of IgG2c (Fig. 3) . Thus, the functions of memory Th2 cells delivering help for B cell versus CD8 T cell responses are differentially affected by the lack of CD40-CD154 costimulation.
Th1, but not Th17, memory helper cells induce humoral responses against donor MHC class I molecules
Our previous studies indicate that spleen rather than bone marrow is the primary source of donor-reactive alloantibodies after heart transplantation in mice (43) . Immunohistochemical staining of spleen sections revealed IgG-producing ASCs in CD40
2/2 recipients injected with unpolarized, Th1, and Th17 cells, but not Th2 cells (Fig. 4A) . Quantitative ELISPOT assay confirmed that the numbers of total IgG spots were significantly increased in recipients containing unpolarized, Th1, and Th17 memory T cells when compared with CD40 2/2 recipients without memory T cell transfer or recipients injected with Th2 Mar cells (Fig. 4B) . Thus, the numbers of IgG-producing cells in the spleen correlated with the observed serum titers of anti-donor IgG alloantibodies. We next assessed the ability of differentiated memory Th cell subsets to induce IgG alloantibodies against representative donor MHC class I molecules. We used ELISPOT assay to measure the frequencies of spleen ASCs secreting IgG reactive to donor H-2D d as we previously published (43) (Fig. 5) . These data indicate that the functional differentiation of memory Th cells impacts the specificity of Ab elicited by an allograft.
Anti-donor alloantibodies induced by Th1 and Th17 memory CD4 T cells differ in their ability to induce complement deposition in the graft Despite the absence of the CD40-CD154 costimulatory pathway and the inability to generate anti-donor IgG alloantibodies, CD40 2/2 mice reject allogeneic heart transplants, even without 1.9 d for recipients containing UP, Th1, Th2, and Th17 cells, respectively), and the rejecting grafts were heavily infiltrated with CD8 + T lymphocytes (data not shown). Thus, although donorreactive alloantibodies induced by transferred memory Mar cells certainly contribute to graft tissue injury, the rapid rejection of heart allografts in this model is predominantly mediated by CD8 effector T cells. To test the potential pathogenicity of alloantibodies induced by CD4 helper cell subsets, we collected serum samples from CD40 2/2 heart allograft recipients containing unpolarized, Th1, Th2, or Th17 memory cells. Serum aliquots were injected into RAG1 2/2 recipients of BALB/c male heart allografts on days 2 and 4 after transplantation, followed by histological analysis of graft tissue on day 7 after transplant. The passive transfer of antidonor sera induced by either unpolarized or Th1 memory Mar cells resulted in intense diffuse C4d deposition in the graft capillaries (Fig. 6 ). The sera from CD40 2/2 allograft recipients containing memory Th2 cells did not induce significant complement deposition, consistent with the low titers of donorreactive IgG alloantibodies. Unexpectedly, despite high titers of donor-reactive Abs induced by Th17 memory Mar cells, transfer of these sera did not lead to C4d deposition in the graft (Fig. 6 ). Taken together, these results suggested that only memory Th cells that secrete IFN-g (unpolarized and Th1 cells, but not Th2 and Th17 cells) are capable of inducing pathogenic anti-donor alloantibody in CD40 2/2 heart allograft recipients.
IFN-g neutralization prevents memory CD4 T cells from providing CD40-independent help to B cells
We directly tested whether IFN-g is required for CD40-independent helper functions of memory CD4 T cells. Administration of blocking anti-IFN-g Ab to CD40
2/2 heart allograft recipients containing unpolarized memory Mar T cells significantly decreased serum titers of IgG2b and IgG2c alloantibodies compared with control rat IgG treatment (Fig. 7A) . Whereas recipients treated with control IgG Ab had reduced numbers of D d -specific ASCs compared with untreated control group, possibly because of the IVIG-like effects of administered Ab, IFN-g neutralization completely prevented generation of donor MHC class I-specific ASCs (Fig. 7C) . In contrast, donor-reactive CD8 T cells were efficiently activated under these conditions, indicating that, in the absence of CD40-CD154 interactions, memory CD4 T cells require IFN-g to provide help to B cells, but that the help for CD8 T cells is IFN-g independent (Fig. 7D) . To extend our findings into a more physiological and clinically relevant transplantation model, we performed adoptive transfer of polyclonal donor-reactive memory CD4 T cells into wild type recipients followed by treatment with anti-CD154 mAb MR1 and heart allograft placement. Consistent with our previously published data (23, 31) , anti-CD154 mAb decreased the numbers of donorreactive ASCs and the serum levels of anti-donor IgG Ab in naive B6 recipients of BALB/c heart allografts ( Fig. 8 and data not  shown) . In contrast, donor-reactive CD4 T cells induced strong antidonor humoral immune responses despite anti-CD154 mAb treatment. Similar to the results observed in CD40 2/2 recipients, IFN-g neutralization significantly inhibited formation of antidonor IgG-secreting cells and donor-reactive IgG alloantibody production (Fig. 8) . Thus, the effects of IFN-g neutralization on the ability of memory Th cells to induce CD40-independent humoral immune responses are not limited to TCR transgenic Th cells and CD40 2/2 recipients.
IFN-g neutralization inhibits expression of BAFF, APRIL, and their receptors
We have recently reported that neutralizing BAFF and a proliferation-inducing ligand (APRIL) synergized with anti-CD154 mAb to reduce anti-donor alloantibody responses and to prolong heart allograft survival in recipients containing donor-reactive memory CD4 T cells (45) . We next tested whether IFN-g secreted by memory CD4 T cells facilitates BAFF/APRIL network signaling in our model. Spleen cell populations were isolated by flow sorting from spleens of CD40 2/2 heart allograft recipients containing unpolarized memory Mar cells. The analyses of mRNA expression revealed that BAFF was expressed exclusively by Gr1 + and F4/80 + cells (neutrophils and monocyte/macrophages, respectively), whereas APRIL was expressed by both of these subsets and additionally by CD11c + dendritic cells (Fig. 9, top) . Administration of anti-IFN-g mAb selectively inhibited BAFF expression in macrophages and APRIL expression in neutrophils. Unexpectedly, CD11c + dendritic cells expressed higher levels of APRIL mRNA after IFN-g blockade. As anticipated, BAFFR was predominantly expressed by B220 + cells, whereas TACI was expressed by both B220 + cells and F4/80 + cells (Fig. 9, bottom) . 
Discussion
The development of donor-reactive memory CD4 and CD8 T cells in the course of heterologous immunity undermines the survival of transplanted allografts. Previous studies of heterologous immunity in transplantation exclusively focused on functions of helper and cytotoxic memory T cells characterized by expression of type 1 cytokines, IFN-g, and TNF-a. However, the human memory T cell repertoire often contains cells programmed to secrete other effector cytokines such as IL-4 and IL-17. The impact of these populations on the course of alloimmune response and transplant rejection has not been previously addressed. Using helper cells with defined specificity for donor Ag, we found that the ability to mount CD40-independent humoral immunity, as well as the isotypes, specificity, and pathogenicity of the resulting alloantibodies, depend on the differentiation profile of memory CD4 T cells. Despite recent interest in Ab-mediated allograft tissue injury, the phenotype and functions of Th cells driving pathogenic alloantibody responses remain poorly defined. A specialized follicular Th cell (T FH ) subset responsible for B cell help was described in multiple models of T-dependent humoral immune responses. The initial findings proposed the existence of a separate T FH cell lineage characterized by high expression levels of CXCR5, CD154, and ICOS and by the enhanced ability to produce IL-21 (46) . Furthermore, T FH cells form functional memory cells in both mice and humans (47) (48) (49) . More recent studies indicate that T cells of distinct functional subsets can enter follicular regions and regulate B cell responses, with the Th1 versus Th2 cytokine profile of Th cells promoting switching to specific Ig isotypes (50, 51) . In addition, IL-17 was reported to facilitate Ab production in autoimmune-prone mice (30) . In our model, all polarized Th cell subsets express comparable levels of CXCR5 upon reactivation (data not shown), but we have previously reported that CD40-independent help by memory T cells occurs in the absence of recipients were collected on days 14 and 21 posttransplant. Pooled serum aliquots were i.v. injected into RAG1 2/2 recipients of BALB/c heart allografts on days 2 and 4 after transplantation (200 ml/injection). After adoptive serum transfer, heart allografts from the RAG1 2/2 recipients were harvested on day 7 after transplant, and immunohistochemical staining for C4d was performed on paraffin-embedded tissue sections. Images are representative of four to five heart allografts analyzed in each group. Original magnification 3200. follicular germinal centers and, therefore, may not require Th cell migration into the follicles (31) .
Whether effector and helper functions of Th2 cells are more dependent on CD40-CD154 signaling than those of Th1 or Th17 cells is controversial. On one hand, CD154-deficient Th2 cells induced via direct CD28 costimulation have been shown to initiate productive humoral responses to adenovirus (52) . Alternatively, CD154-CD40 blockade ameliorates Th2-mediated diseases such as Graves' disease, collagen-induced arthritis, and hapten-induced dermatitis, and efficiently prolongs heart allograft survival in Th2-prone STAT4
2/2 recipients (53). Even more relevant to our study, the ability of Th2 cells to provide help for extrafollicular plasma cell responses is compromised in CD154-deficient mice (54) . Our findings suggest that the Th2 help delivered for B cell versus CD8 T cell responses may have distinct requirements for CD40-CD154 interactions.
In contrast with Th1 and Th17 polarized memory T cells, Th2 cells were incapable of inducing high titers of donor-reactive IgG alloantibodies in CD40 2/2 recipients. This is consistent with the observation that unpolarized memory CD4 T cells in wild type recipients treated with anti-CD154 Ab do not induce high titers of anti-donor IgG1, an isotype typically associated with Th2 immunity (Fig. 1) . In a recent study, human Th2 and Th17 cells, but not Th1 cells, induced Ab isotype switch when cocultured with naive B cells in vitro (55) . The differences between this report and our data are likely due to the additional factors contributing to in vivo versus in vitro T cell-mediated help. Our data suggest that the measurement of serum anti-donor alloantibodies by standard techniques may not correspond to the pathologic findings in the graft. Despite comparable titers of donorreactive alloantibodies in CD40 2/2 recipients containing memory Th1 and Th17 cells, the induced Ab differ in their ability to mediate allograft tissue injury (Fig. 4) . Whereas the adoptive transfer of donor-reactive sera or mAbs into immunodeficient recipients usually fails to cause heart allograft failure, C4d deposition is commonly used to assess the pathogenicity of induced alloantibodies (56) . We are currently investigating whether the distinction between Th1-and Th17-induced alloantibodies in our model may be attributed to differences in alloantibody specificity (MHC class I and II and potentially autoantigens), affinity, and isotype distribution (shift from IgG2b and IgG2c to IgG1). Although memory CD4 T cells increased antidonor IgM responses in CD40
recipients, the numbers of donor-reactive IgM-secreting cells under CD40-deficient conditions were consistently 6-to 8-fold lower than those in wild type recipients regardless of IFN-g neutralization (data not shown). In addition, the pathogenic role of antidonor IgM alloantibodies in allograft rejection remains controversial (57-62). Therefore, our future studies will initially focus on donor-reactive IgG alloantibodies. Instead of complement activation, alloantibodies induced by Th17 cells may bind to endothelial cells and stimulate release of proinflammatory cytokines and chemokines, exocytosis of von Willebrand factor, and Pselectin and cell proliferation (63) . However, this is unlikely as such functions are mostly described for Abs that cross-link MHC class I molecules, and alloantibodies of this specificity are not efficiently induced by Th17 memory cells (Fig. 5) . Consistent with the finding that the alloantibodies induced by memory CD4 T cells in a CD40-independent manner are dominated by IgG2b and IgG2c isotypes, these responses were inhibited by anti-IFN-g Ab administration. Importantly, IFN-g neutralization had similar effects in wild type recipients containing polyclonal memory CD4 T cells and treated with anti-CD154 mAb, demonstrating that our findings are not limited to TCR transgenic Th cells and CD40 2/2 recipients. Litinskiy et al. (64) have demonstrated that BAFF and APRIL produced by human dendritic cells can induce CD40-independent Ig class switching in vitro. We recently reported that neutralizing BAFF and APRIL inhibits CD40-independent helper functions of memory CD4 T cells in heart allograft recipients (45) . Previous studies in tumor and autoimmunity models demonstrated that IFN-g, among other proinflammatory cytokines, enhances BAFF and APRIL production by various cell types and upregulates BAFFR expression on B cells (47, 48, (65) (66) (67) . In accordance with these findings, our results suggest mechanistic link between IFN-g secreted by memory CD4 T cells and the effects of BAFF/APRIL cytokine signaling in the absence of CD40 (Fig. 9) . Whereas IFN-g neutralization inhibits expression of BAFF, APRIL, and their receptors, we previously showed that blocking BAFF and APRIL decreases the ability of memory CD4 T cells to secrete IFN-g and differentiate into T FH (45) . Therefore, it is possible that B cells stimulated through BCR and BAFFR may further enhance IFN-g secretion by Th cell, thus establishing positive feedback loop resulting in alloantibody isotype switching to IgG2b and IgG2c in the absence of CD40-CD154 interactions. In addition, IFN-g may enhance the Ag processing and presentation of donor Ags by B cells, thus stabilizing cognate T-B cell interactions necessary for alloantibody production. Studies distinguishing between these possibilities and determining cellular targets of IFN-g in this model are ongoing in our laboratory. Taken together, our data show that donor-reactive helper memory T cells secreting IFN-g drive generation of pathogenic alloantibodies under conditions of limited CD40 costimulation. These insights may be used to identify individuals with high risk for de novo alloantibody production based on analysis of their memory T cell repertoire before transplantation and to design therapies that target humoral immune responses in T cell-sensitized recipients. Because several reagents targeting CD40-CD154 costimulatory pathway are being developed and tested in preclinical models, our findings may have significant implications for the future use of CD40-directed costimulatory blockade in human transplant patients. 
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